文献速递甲状腺与浅表US

超声引导下经皮聚多卡醇注射与经皮无水乙醇注射治疗良性囊性甲状腺结节的比较

Comparison of Ultrasound-Guided Percutaneous Polidocanol Injection Versus Percutaneous Ethanol Injection for Treatment of Benign Cystic Thyroid Nodules.
PubMed 文献 · J Ultrasound Med · 2017-12-08

回顾性纳入2010年5月至2016年3月间经皮无水乙醇注射治疗的135个囊性甲状腺结节和经皮聚多卡醇注射治疗的136个囊性甲状腺结节,随访1、3、6、12个月。两组在结节体积缩小、体积缩小率和治疗成功率方面无显著差异(P > .05),无水乙醇组并发症发生率高于聚多卡醇组(P < .05),但聚多卡醇注射费用高于无水乙醇注射(97.18±22.17美元 vs 43.36±5.51美元;P < .01)。结论认为超声引导下经皮聚多卡醇注射可作为囊性或主要为囊性甲状腺结节硬化治疗的替代选择,但其费用高于经皮无水乙醇注射。

要点

  • 囊性和主要为囊性甲状腺结节中,聚多卡醇与无水乙醇在结节体积缩小、体积缩小率及治疗成功率上无显著差异(P > .05)。
  • 末次随访时两组美容评分(P = .59;P = .42)和症状评分(P = .32;P = .73)在囊性及主要为囊性结节中均无显著差异。
  • 无水乙醇组并发症发生率高于聚多卡醇组(P < .05),但聚多卡醇注射费用更高(97.18±22.17美元 vs 43.36±5.51美元;P < .01)。

核心结论

  • 超声引导下经皮聚多卡醇注射可作为囊性或主要为囊性甲状腺结节硬化治疗的替代选择,但其费用高于经皮无水乙醇注射。

研究设计与样本

  • 回顾性研究,纳入经皮无水乙醇注射治疗的135个囊性甲状腺结节和经皮聚多卡醇注射治疗的136个囊性甲状腺结节,治疗时间为2010年5月至2016年3月,随访1、3、6、12个月。

诊断标准与关键数值

  • 两组在囊性和主要为囊性甲状腺结节随访期间结节体积缩小、体积缩小率及治疗成功率均无显著差异(P > .05);末次随访时美容评分(P = .59;P = .42)和症状评分(P = .32;P = .73)在囊性及主要为囊性结节中均无显著差异;无水乙醇组并发症发生率高于聚多卡醇组(P < .05);聚多卡醇注射费用高于无水乙醇注射(均值±标准差,97.18±22.17美元 vs 43.36±5.51美元;P < .01)。

临床应用与阅片要点

  • 作者认为超声引导下经皮聚多卡醇注射可作为囊性或主要为囊性甲状腺结节硬化治疗的替代选择,同时指出其费用高于经皮无水乙醇注射。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We compared the efficacy, safety, and cost-effectiveness of ultrasound-guided percutaneous polidocanol injection and percutaneous ethanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.

METHODS: A total of 135 cystic thyroid nodules treated by percutaneous ethanol injection and 136 cystic thyroid nodules treated by percutaneous polidocanol injection were enrolled retrospectively in this study from May 2010 to March 2016. The nodules were followed after 1, 3, 6, and 12 months. Nodule volumes, symptoms scores, and cosmetic scores were assessed before treatment and at follow-up. The therapeutic success rate, safety, and cost-effectiveness between the groups were also compared.

RESULTS: No significant differences in the reduction of the nodule volume, volume reduction rate, and therapeutic success were observed between the groups with cystic and predominantly cystic thyroid nodules during follow-up (P > .05). Neither the cosmetic scores (P = .59; P = .42) nor the symptom scores (P = .32; P = .73) in the cystic and predominantly cystic nodules were significantly different between the groups at the last follow-up. The complication rates for ethanol were higher than those for polidocanol (P < .05). However, the cost of polidocanol injection was higher than that of ethanol injection for cystic thyroid nodules (mean ± SD, US$97.18 ± US$22.17 versus US$43.36 ± US$5.51; P < .01).

CONCLUSIONS: Ultrasound-guided percutaneous polidocanol injection can be an alternative for sclerotherapy of cystic or predominantly cystic thyroid nodules. However, its cost was higher than that of percutaneous ethanol injection.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Gong X, Wang F, Du H, et al. Comparison of Ultrasound-Guided Percutaneous Polidocanol Injection Versus Percutaneous Ethanol Injection for Treatment of Benign Cystic Thyroid Nodules. J Ultrasound Med. 2017. PMID: 29219197. doi:10.1002/jum.14482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。